Kilitch Drugs (India) Limited (KILITCH.BO)
INR 334.6
(-0.54%)
INR 334.6
(-0.54%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 208.05 Million INR | 43.2% |
| 2022 | 145.28 Million INR | 61.7% |
| 2021 | 89.85 Million INR | 148.29% |
| 2020 | 36.18 Million INR | 373.61% |
| 2019 | -13.22 Million INR | -121.17% |
| 2018 | 62.48 Million INR | 56.47% |
| 2017 | 39.93 Million INR | 134.99% |
| 2016 | -114.14 Million INR | 1.85% |
| 2015 | -116.28 Million INR | -1126.39% |
| 2014 | -9.48 Million INR | -189.19% |
| 2013 | 10.63 Million INR | -67.54% |
| 2012 | 32.75 Million INR | -96.64% |
| 2011 | 973.62 Million INR | 644.17% |
| 2010 | 130.83 Million INR | -27.65% |
| 2009 | 180.82 Million INR | 42.3% |
| 2008 | 127.07 Million INR | -0.13% |
| 2007 | 127.23 Million INR | 851.45% |
| 2006 | 13.37 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 8.07 Million INR | -86.86% |
| 2023 Q4 | 61.48 Million INR | 319.63% |
| 2023 Q1 | 53.89 Million INR | 1.7% |
| 2023 Q2 | 78.02 Million INR | 44.79% |
| 2023 Q3 | 14.65 Million INR | -81.22% |
| 2023 FY | 208.05 Million INR | 43.2% |
| 2022 Q2 | 30.66 Million INR | 18.05% |
| 2022 Q4 | 52.98 Million INR | 73.56% |
| 2022 FY | 145.28 Million INR | 61.7% |
| 2022 Q1 | 25.97 Million INR | -33.74% |
| 2022 Q3 | 30.53 Million INR | -0.42% |
| 2021 Q3 | 5.64 Million INR | -80.92% |
| 2021 Q1 | 4.59 Million INR | 361.43% |
| 2021 FY | 89.85 Million INR | 148.29% |
| 2021 Q4 | 39.2 Million INR | 594.31% |
| 2021 Q2 | 29.59 Million INR | 543.86% |
| 2020 FY | 36.18 Million INR | 373.61% |
| 2020 Q4 | -1.75 Million INR | -106.09% |
| 2020 Q3 | 28.86 Million INR | 0.11% |
| 2020 Q2 | 28.83 Million INR | 334.8% |
| 2020 Q1 | -12.28 Million INR | 9.5% |
| 2019 FY | -13.22 Million INR | -121.17% |
| 2019 Q1 | 2.1 Million INR | -93.59% |
| 2019 Q2 | 18.47 Million INR | 778.69% |
| 2019 Q3 | 16.23 Million INR | -12.12% |
| 2019 Q4 | -13.57 Million INR | -183.61% |
| 2018 FY | 62.48 Million INR | 56.47% |
| 2018 Q4 | 32.76 Million INR | 187.42% |
| 2018 Q3 | -37.48 Million INR | -164.14% |
| 2018 Q2 | 58.44 Million INR | 14.29% |
| 2018 Q1 | 51.13 Million INR | 0.0% |
| 2017 FY | 39.93 Million INR | 134.99% |
| 2016 FY | -114.14 Million INR | 1.85% |
| 2015 FY | -116.28 Million INR | -1126.39% |
| 2014 FY | -9.48 Million INR | -189.19% |
| 2013 FY | 10.63 Million INR | -67.54% |
| 2012 Q4 | 4.26 Million INR | -32.83% |
| 2012 Q3 | 6.34 Million INR | 489.5% |
| 2012 Q2 | -1.62 Million INR | -105.6% |
| 2012 FY | 32.75 Million INR | -96.64% |
| 2012 Q1 | 29.07 Million INR | 0.0% |
| 2011 FY | 973.62 Million INR | 644.17% |
| 2010 FY | 130.83 Million INR | -27.65% |
| 2009 FY | 180.82 Million INR | 42.3% |
| 2008 FY | 127.07 Million INR | -0.13% |
| 2007 FY | 127.23 Million INR | 851.45% |
| 2006 FY | 13.37 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Aarti Drugs Limited | 7.14 Billion INR | 97.09% |
| NATCO Pharma Limited | 25.96 Billion INR | 99.199% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 93.349% |
| RPG Life Sciences Limited | 2.29 Billion INR | 90.924% |
| Shilpa Medicare Limited | 1.36 Billion INR | 84.772% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 95.485% |
| Alkem Laboratories Limited | 19.46 Billion INR | 98.931% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 99.179% |
| Venus Remedies Limited | 534.65 Million INR | 61.087% |
| Lasa Supergenerics Limited | -458 Million INR | 145.425% |
| Ind-Swift Limited | 1.22 Billion INR | 83.03% |
| Hester Biosciences Limited | 364.81 Million INR | 42.97% |
| Indoco Remedies Limited | 1.29 Billion INR | 83.904% |
| Bal Pharma Limited | 233.9 Million INR | 11.055% |
| Hikal Limited | 32.11 Million INR | -547.929% |
| Achyut Healthcare Limited | 4.43 Million INR | -4587.922% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 95.294% |
| Ajanta Pharma Limited | 19.67 Billion INR | 98.943% |
| Alpa Laboratories Limited | 184.49 Million INR | -12.766% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 87.886% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 99.507% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -2194.155% |
| Brooks Laboratories Limited | 14.44 Million INR | -1340.789% |
| Nectar Lifesciences Limited | 923.8 Million INR | 77.479% |
| Divi's Laboratories Limited | 33.08 Billion INR | 99.371% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.693% |
| Eris Lifesciences Limited | 5.18 Billion INR | 95.985% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 96.8% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 97.683% |
| Granules India Limited | 6.81 Billion INR | 96.948% |
| Gufic Biosciences Limited | 1.32 Billion INR | 84.356% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 86.971% |
| Ipca Laboratories Limited | 7.98 Billion INR | 97.393% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 95.991% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 236.914% |
| Laurus Labs Limited | 3.94 Billion INR | 94.731% |
| Mankind Pharma Limited | 21.51 Billion INR | 99.033% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -107.428% |
| Megasoft Limited | -121.1 Million INR | 271.794% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 92.532% |
| Piramal Pharma Limited | 4.55 Billion INR | 95.434% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Sigachi Industries Limited | 1.47 Billion INR | 85.884% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 105.4% |
| Strides Pharma Science Limited | 5.22 Billion INR | 96.019% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.801% |
| Themis Medicare Limited | 392.58 Million INR | 47.006% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | 63.482% |
| Windlas Biotech Limited | 1.29 Billion INR | 83.982% |
| Wockhardt Limited | -670 Million INR | 131.052% |
| ZIM Laboratories Limited | 253.82 Million INR | 18.035% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 83.099% |
| Suven Life Sciences Limited | -1.22 Billion INR | 116.972% |
| Amrutanjan Health Care Limited | 457.54 Million INR | 54.529% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 96.387% |
| Lupin Limited | 28.04 Billion INR | 99.258% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 105.056% |
| Syncom Formulations (India) Limited | 249.25 Million INR | 16.53% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 99.517% |
| FDC Limited | 2.98 Billion INR | 93.033% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 98.543% |
| Novartis India Limited | 626.5 Million INR | 66.792% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 59.056% |
| Neuland Laboratories Limited | 5.31 Billion INR | 96.088% |
| Morepen Laboratories Limited | 4.17 Billion INR | 95.015% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -657.703% |